Evidence map›Paper›PMID 41831237›Full record

ArticleThe Journal of antimicrobial chemotherapy2026

Diagnosis and risk factors for invasive mould disease-a round table discussion on directing antifungal therapy according to the available evidence.

Ana Alastruey-Izqueirdo, Johan Maertens, Monica A Slavin, Paul E Verweij, P Lewis White

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Alastruey-IzqueirdoMycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain and Center for Biomedical Research in Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-8651-4405
Johan MaertensDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven and Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
Monica A SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.ORCID 0000-0002-8443-314X
Paul E VerweijDepartment of Medical Microbiology and Radboudumc-CWZ Centre of Expertise for Mycology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID 0000-0002-8600-9860
P Lewis WhitePublic Health Wales Mycology Reference Laboratory, UHW, Cardiff, UK.

Funding

Pfizer Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41831237
PMCPMC13098179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.